OOIR: Observatory of International Research

Papers

(The median citation count of Neurology-Neuroimmunology & Neuroinflammation is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	167
MOG IgG3-Subclass Antibodies in MOG-Associated Disease	94
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	92
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	80
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	80
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	71
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	70
Antibody-Negative Autoimmune Encephalitis	70
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	69
Elevated ITGAX/CD11c in CSF-Derived Extracellular Vesicles Reflects Disability Progression in Multiple Sclerosis	67
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	64
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	63
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	63
Peripheral HLA-DR ^hi CD141 ⁺ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis	62
Treatment With Erythropoietin for Patients With Optic Neuritis	61
Plasma N -Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD, and MOGAD	61
Acute Paresthesia and Ataxia in a Child	61
Should We Measure CSF Complement Levels in Patients With MOGAD?	60
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	58
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	56
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	53
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	51
Toward Precision Phenotyping of Multiple Sclerosis	51
Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis	50
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	49

Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	48
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	47
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	47
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	47
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	46
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis	45
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	44
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	43
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	41
Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis	39
Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders	38
Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis	37
Inside the Heterogeneity of Primary CNS Vasculitis	36
Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls	36
Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	36
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	35
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	35
Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy	34
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	34
Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity	33
“Will the Real Demyelinating Disorder Please Stand Up?”	33
Pediatric MOG-Ab–Associated Encephalitis	32
Acknowledgment to Reviewers	32
Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis	32
Absence of Systemic Oxidative Stress and Increased CSF Prostaglandin F2α in Progressive MS	32
Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate	32
Spironolactone Targets Retinoid X Receptor γ to Promote Myelin Sheath Regeneration	32
Relative Frequency and Distinctive Features of Anti-Ma2 Nonparaneoplastic Neurologic Disorders	31
A 42-Year-Old Woman With Rapidly Expanding White Matter Lesions	31
Chronic Dengue Virus Encephalitis	30
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	30
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	30
Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis	30
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease	30
Neurologic Manifestations of Common Variable Immunodeficiency	30
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient	30
Immune Effector Cell–Associated Neurotoxicity Delayed Relapse After Chimeric Antigen Receptor T-Cell Therapy	29
Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients	29
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	29
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models	29
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study	29
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab	29
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis	28
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis	27
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies	27
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis	27
Distinct Epitopes Are Associated With Clinical Phenotypes in Autoimmune Nodopathies With Anti-Contactin1 Autoantibodies	26
Brain-Resident MAIT Cells Infiltrate GL261 Tumors, and Activated MAIT Cell Signatures Are Associated With Improved Outcomes in Glioma	26
Fulminant Amyloid β–Related Angiitis With Herniation and Rapid Response to Tocilizumab	25
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	25

Distinguishing Transient From Persistent Brain Structural Changes in Pediatric Patients With Acute Disseminated Encephalomyelitis	25
Complement C4d Informs the Differential Diagnosis of Inflammatory Demyelinating CNS Diseases	25
Ten Years of Neurology ® Neuroimmunology & Neuroinflammation	25
HTLV-1–Infected CD4 ⁺ T Cells Drive Spontaneous Lymphoproliferation and Virus-Specific CD8 ⁺ Cytot	25
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis	25
Chronic Active Lesions and Larger Choroid Plexus Explain Cognition and Fatigue in Multiple Sclerosis	24
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis	24
Clinical Characterization and Ancillary Tests in Susac Syndrome	24
Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis	24
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	23
Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan	23
PET Study of Microglial Activation in Kleine-Levin Syndrome	23
Progressive Encephalomyelopathy in an Older Man	23
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	23
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis	23
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	23
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	23
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	23
Pregnancy and Infant Outcomes in Multiple Sclerosis	23
Reduced Hospital Incidence of Autoimmune Encephalitis During the COVID-19 Pandemic	23
MIF Tautomerase Inhibition Protects Neurons From Immune-Mediated Cell Death	23
Iatrogenic Cerebral Amyloid Angiopathy–Related Inflammation	22
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	22
Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease–Driving Inflammation While Promoting Regulatory B Cells	22
Proinflammatory Effect of Mesenchymal Stem Cells From Patients With Multiple Sclerosis	22
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	22
Pediatric MOG-Ab–Associated Encephalitis	21
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	21
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I)	21
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	21
Neuropsychological Testing in Autoimmune Encephalitis	21
Multiple Sclerosis in the Emergency Department	21
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	21
Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis	21
Extensive Corticospinal Tract Involvement in a Patient With Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	21
Progressive Myelitis in a 63-Year-Old Woman	20
Ravulizumab and Efgartigimod in Myasthenia Gravis	20
EBV Dysregulation Is Associated With Immune Imbalance in Multiple Sclerosis	20
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	19
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	19
Cerebellar Ataxia With Anti-DNER Antibodies	19
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	19
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	19
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	19
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	19
Progression Independent of Relapse Activity in Aquaporin-4-IgG–Positive NMOSD	19
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	18
A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement	18
Antibody Investigations in 2,750 Children With Suspected Autoimmune Encephalitis	18
Cytomegalovirus Drives the Development of Cytotoxic CD4 ⁺ T Cells in Patients With Multiple Sclerosis	18
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	18
Genomic and Serologic Characterization of Enterovirus A71 Brainstem Encephalitis	18
Inflammatory Activity After Diverse Fertility Treatments	18
Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis	18
Paraneoplastic Brachial Amyotrophic Diplegia With Favorable Outcome and Anti-Ank3 Antibodies	18
Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years	18
Spinal Cord Leptomeningeal Enhancement as a Marker of Extensive Spinal Cord Involvement in Children With MOGAD	17
Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies	17
Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade	17
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	17
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders	17
Single-Cell Multi-Omics Map of Cell Type–Specific Mechanistic Drivers of Multiple Sclerosis Lesions	17
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure	17
Immunity Gone Viral	17
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	16
Emerging CSF and Serum Biomarkers in Multiple Sclerosis	16
Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli	16
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis	16
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis	16
Microglia as Central Protagonists in the Chronic Stress Response	16
Movement Disorders in Antibody-Associated Neurologic Diseases	16
Comparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With Onchocerca volvulus	16
Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease	15
Real-Life Evaluation of the MOGAD Diagnostic Criteria	15
Antibodies Against Glutamic Acid Decarboxylase 65 Are Locally Produced in the CSF and Arise During Affinity Maturation	15
Pregnancy and Infant Outcomes in Multiple Sclerosis	15
Decoding TREM2 Signaling Pathways	15
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease	15
Retrospective Pediatric Cohort Study Validates NEOS Score and Demonstrates Applicability in Children With Anti-NMDAR Encephalitis	15
Clearance of Early Complement Protein From CSF After Aneurysmal Subarachnoid Hemorrhage and Influence on Neurologic Outcome	15

Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling	15
The Inner Nuclear Layer in Pediatric Multiple Sclerosis	15
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis	15
Primary Angiitis of the CNS	15
Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders	14
Abnormal B-Cell Exosome Proapoptotic and Antiapoptotic Cargo in Multiple Sclerosis	14
Multiple Sclerosis	14
Serum Autoantibody Titers and Neurofilament Light Chain Levels in CASPR2/LGI1 Encephalitis	14
Intrathecal CD8 ⁺ CD20 ⁺ T Cells in Primary Progressive Multiple Sclerosis	14
Cardiac Involvement in Neurosarcoidosis	14
Prolonged Corticosteroids Without Maintenance Immunotherapy for Treatment of Anti-LGI1 Encephalitis	14
MOG Antibody–Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use	14
Oral and Gut Dysbiosis in Migraine	14
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension	14
SARS-CoV-2 Vaccines and Multiple Sclerosis	14
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies	14
CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage	13
Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis	13
Reemerging Infectious Diseases and Neuroimmunologic Complications	13
Acknowledgment to Reviewers	13
Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates	13
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology	13
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration	13
Electrolyte Imbalance in Anti LGI1 Encephalitis	13
CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis	13
OCT-Based Differentiation of First Acute Optic Neuritis	13
Epstein-Barr Virus in Multiple Sclerosis	13
IgM Anti-Ganglioside Binding and Complement Activation in an iPSC-Derived Motor Neuron Model for Multifocal Motor Neuropathy	13
Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction	12
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis	12
Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis	12
TRUE-MOGAD Score	12
Acknowledgment to Reviewers	12
Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS	12
Clinical Features and Biomarkers Associated With Intensive Care–Dependent Refractory NMDAR Encephalitis	12
Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice	12
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis	12
Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments	12
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series	12
Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis	12
Brain Immune Cell Composition in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy After Natalizumab	12
Clinical Characterization and Long-Term Outcome in Children and Adults With Anti-AMPA Receptor Encephalitis	12
Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus	12
Amaurosis Fugax Dolorosa	12
Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy	11
Therapies in Stiff-Person Syndrome	11
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis	11
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis	11
Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis	11
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography	11
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab	11
Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis	11
Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis	11
Alterations of Thymus-Derived Tregs in Multiple Sclerosis	11
Multiple Sclerosis, Disease-Modifying Therapies, and Infections	11
Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis	11
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder	11
Relapsing White Matter Disease and Subclinical Optic Neuropathy	11
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis	11
Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion	10
Defining the Clinicoradiologic Syndrome of SARS-CoV-2 Acute Necrotizing Encephalopathy	10
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome	10
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis	10
White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity	10
Lifespan Modeling of Choroid Plexus Volume in Multiple Sclerosis and Its Dynamic Associations With Clinical, MRI, and HLA Susceptibility	10
Pachymeningitis in Biopsy-Proven Sarcoidosis	10
Enterovirus Encephalitis in People With Multiple Sclerosis on Ocrelizumab	10
Promising Effects of CAR T-Cell Therapy in Refractory Stiff Person Syndrome and a Hopeful Future for All Neuroautoimmunities	10
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II)	10
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	10
Late-Onset Anti-GABA _B Receptor Encephalitis	10
Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis	10
Trajectories of Inflammatory Markers and Post–COVID-19 Cognitive Symptoms	10
Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease	10
Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy	10
Post-COVID Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy	10
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD	10
Acute Optic Neuropathy in Older Adults	10
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome	10
Micro-RNA Signature in CSF Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	9
Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey	9
Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia	9
Mesiotemporal Volumetry, Cortical Thickness, and Neuropsychological Deficits in the Long-term Course of Limbic Encephalitis	9
LGI1 Autoantibodies Enhance Synaptic Transmission by Presynaptic K _v 1 Loss and Increased Action Potential Broadening	9
High and Persistent Anti-GM1 Antibody Titers Are Associated With Poor Clinical Recovery in Guillain-Barré Syndrome	9
CNS Inflammation as the First Sign of Complement Factor I Deficiency	9
Corrections to Preprint Server Information	9
Management of Autoimmune Encephalitis in a 7-Year-Old Child With CTLA-4 Haploinsufficiency and AMPA Receptor Antibodies	9
Single-Cell Transcriptomics Identifies Brain Endothelium Inflammatory Networks in Experimental Autoimmune Encephalomyelitis	9
Patient-Reported Outcome Measures in NMDA Receptor Encephalitis	9
Anti–GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab	9
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis	9
Focal Motor Seizures as a Manifestation of Rheumatoid Meningitis	9
Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder	9
Inflammatory Cytokine Signatures Are Associated With Disease Burden and Comorbidity of Episodic Migraine and Endometriosis	9